Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;5(5):790-7.
doi: 10.2215/CJN.04120609. Epub 2010 Feb 25.

Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation

Ben Sprangers  1 , George Ian Lefkowitz, Scott D Cohen, Michael Barry Stokes, Antony Valeri, Gerald B Appel, Cheryl L Kunis
Affiliations

Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation

Ben Sprangers et al. Clin J Am Soc Nephrol. 2010 May.

Abstract

Background and objectives: Recurrence of the original kidney disease after renal transplantation is an increasingly recognized cause of allograft loss. Idiopathic membranous nephropathy (iMN) is a common cause of proteinuria that may progress to ESRD. It is known that iMN may recur after kidney transplantation, causing proteinuria, allograft dysfunction, and allograft loss. Limited data regarding the frequency and treatment of recurrent iMN are available.

Design, setting, participants, & measurements: In this single-center study, all patients who had iMN and were receiving a first kidney transplant were included. We retrospectively assessed the incidence of biopsy-confirmed recurrent iMN and compared clinical characteristics of patients with and without recurrence. In addition, the effect of treatment with rituximab on proteinuria and renal allograft function in patients with recurrent iMN was examined

Results: The incidence of recurrent iMN was 44%, and recurrences occurred at a median time of 13.6 months after transplantation. Two patterns of recurrence were identified: Early and late. No predictors of recurrence or disease progression could be identified. Treatment with rituximab was effective in four of four patients in stabilizing or reducing proteinuria and stabilizing renal function.

Conclusions: Recurrence of iMN is common even in the era of modern immunosuppression. Rituximab seems to be a valuable treatment option for these patients, although lager studies are needed to confirm our data.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence of recurrent iMN was constructed using Kaplan-Meier plots.
Figure 2.
Figure 2.
Effect of rituximab treatment on the urine protein/urine creatinine ratio (A) and serum creatinine (B).
See this image and copyright information in PMC

References

    1. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ: Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347: 103– 109, 2002 - PubMed
    1. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am J Kidney Dis 35: 157– 165, 2000 - PubMed
    1. Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 16: 1188– 1194, 2005 - PubMed
    1. Cosyns JP, Couchoud C, Pouteil-Noble C, Squifflet JP, Pirson Y: Recurrence of membranous nephropathy after renal transplantation: Probability, outcome and risk factors. Clin Nephrol 50: 144– 153, 1998 - PubMed
    1. Poduval RD, Josephson MA, Javaid B: Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol 23: 392– 399, 2003 - PubMed

Publication types

MeSH terms

LinkOut - more resources